Caitlin Raymond on Platelet Refractoriness: New Series Alert!
Caitlin Raymond, a board-certified Clinical Pathologist and current Transfusion Medicine Fellow at the National Institutes of Health, shared on LinkedIn:
“New Blog Post: Platelet Refractoriness — An Overview
One of the most frustrating challenges in transfusion medicine is when platelet transfusions don’t “stick.”
Platelet refractoriness is common, multifactorial, and has huge implications for bleeding risk, patient outcomes, and stewardship of scarce blood products.
In this post, I walk through:
- How we define and measure refractoriness (CCI)
- Why non-immune causes (like sepsis, bleeding, or splenomegaly) are the most common and should be ruled out first
- How we evaluate immune causes with HLA typing, antibody screens, PRA, and crossmatches
- Practical management strategies, from HLA-compatible platelets to PRA-guided selection
- The real-world challenges of balancing ideal care with limited resources
Key takeaway: Refractoriness isn’t rare—and a structured approach can make transfusion both safer for patients and more sustainable for the blood supply.”
Read the full post here.
More from Caitlin Raymond featured in HT!
More series on coagulation featured in Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia